Navigation Links
Signalife Receives FDA Clearance for OTC Non-Prescription Event Recorder Device
Date:11/26/2007

LOS ANGELES, Nov. 26 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN - News) has received FDA 510(k) clearance to market and sell - without prescription - its ambulatory event recorder throughout the United States. This device, which Signalife will market as the Fidelity 200 HeartLife Tempo Card, is a direct-to-consumer non-prescription flexible credit card- sized heart monitoring device which will be used as an early-detection device by patients who desire to independently monitor their condition. The HeartLife Tempo Card uses the award-winning amplification technology contained in Signalife's Fidelity 100 Heart Monitor. In operation, at the onset of an event that will be recorded, the patient will hold the event recorder to his/her chest, press the "record" button, and record up to a 45-second event. The event recorder will be capable of storing up to six, 45-second recordings. The patient will then either take the recorder to his or her physician for review, or transmit the data to a subscription-based 24-hour monitoring center where it can be immediately evaluated by a qualified ECG technician, cardiac nurse or cardiologist.

With the sensitivity of the amplification technology used in the Fidelity 200 HeartLife Tempo Card - developed by Signalife's Chief Technology Officer and renowned scientist Dr. Budimir Drakulic - the Company believes it will be able to allow patients to effectively monitor their hearts anytime, anyplace, without the necessity of a prescription or other physician intervention. This, in turn, will lead to additional care and may lead to earlier intervention and other preventative measures for cardiovascular disease - the most costly of all diseases nationwide with annual expenditures approaching $400,000,000 spent across the country.

Dr. Lowell Harmison - the Company's CEO and former official for the United States in various regulatory health care capacities, including Principal Deputy Assistant Secretary for Health
'/>"/>

SOURCE Signalife, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Signalife Provides Corporate Update
2. Legendary Earvin Magic Johnson Joins AFL/Signalife Cardiovascular Protection Team
3. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
4. Signalife Achieves $1.98 Million Sales Orders Thus Far
5. Signalife Receives Another $3.3 Million Sales Orders
6. NFL Hall of Fame Legend Fred Biletnikoff Joins AFL/Signalife Cardiovascular Protection Team
7. Signalife Continues to Procure Purchase Orders, Revenues
8. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
9. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
10. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
11. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... INCLINE VILLAGE, Nev. , July 28, 2015 /PRNewswire/ ... PDLI ) today announced that the Company will release ... ended June 30, 2015, on Wednesday, August 5, 2015, ... call and webcast that day at 4:30 p.m. Eastern ... relating to the call will be available via the ...
(Date:7/28/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/z54c4k/biomedical ) has ... and Freezers Market - Global Industry Analysis, Size, ... report to their offering. ... been segmented based on applications: hospitals, research laboratories, ... others segment includes applications of biomedical refrigerators and ...
(Date:7/28/2015)...  Moerae Matrix Inc. announced today the initiation ... MMI-0100, a first-in-class inhibitor of MAPKAP kinase 2 ... characterized by inflammation and fibrosis.  The study, conducted ... is a double-blind, two-way cross-over design lipopolysaccharide (LPS) ... of MMI-0100 when given via inhalation to healthy ...
(Date:7/28/2015)... Israel , July 28, 2015 ... a regenerative medicine company utilizing its proprietary plant-based ... that Shomrat Shurtz has been appointed Senior Director ...      (Photo: http://photos.prnewswire.com/prnh/20150728/246955 ) , ... of experience in marketing, regulatory and business strategy. ...
Breaking Biology Technology:PDL BioPharma to Announce Second Quarter 2015 Financial Results on August 5, 2015 2Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015 2Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015 3Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2CollPlant Names Shomrat Shurtz Senior Director of Business Development 2
... UOP LLC, a Honeywell (NYSE: HON ... for use in Rentech, Inc.,s Rialto Renewable Energy Center ... The renewable energy center, to be built in ... tree trimmings, into renewable, ultra-clean diesel fuel and renewable ...
... 1 PDL BioPharma, Inc. (PDL) (Nasdaq: ... quarter ended September 30, 2010 of approximately $86 million, ... the third quarter of 2009, a 20 percent year-over-year ... quarter 2010 sales of Avastin®, Herceptin®, Lucentis® and Tysabri® ...
... cotton cloth in a high-tech broth full of silver nanowires ... low-cost filter that could easily be implemented to purify water ... bacteria as most existing filters do, the new filter lets ... time the pathogens have passed through, they have also passed ...
Cached Biology Technology:Honeywell UOP Technology Selected to Support Conversion of Biomass to Fuel at California Renewable Energy Facility 2Honeywell UOP Technology Selected to Support Conversion of Biomass to Fuel at California Renewable Energy Facility 3PDL BioPharma Provides Third Quarter 2010 Revenue Guidance of Approximately $86 Million and Update to its Correspondence With Genentech 2PDL BioPharma Provides Third Quarter 2010 Revenue Guidance of Approximately $86 Million and Update to its Correspondence With Genentech 3PDL BioPharma Provides Third Quarter 2010 Revenue Guidance of Approximately $86 Million and Update to its Correspondence With Genentech 4PDL BioPharma Provides Third Quarter 2010 Revenue Guidance of Approximately $86 Million and Update to its Correspondence With Genentech 5High-speed filter uses electrified nanostructures to purify water at low cost 2High-speed filter uses electrified nanostructures to purify water at low cost 3High-speed filter uses electrified nanostructures to purify water at low cost 4
(Date:7/21/2015)... 21, 2015 Today, ZTE announced its Android ... well as expected revenues in 2015 that relate to sales of ... guidance of approximately 2,200 MSEK for 2015. Jörgen Lantto, ... smartphone manufacturer in China and we are ... 5 for Axon , its ...
(Date:7/20/2015)... DENVER , July 20, 2015  Acuity ... Mobility Report: The Convergence of Commerce and Privacy" ... billion mobile biometric apps will be downloaded to ... users. The mobile biometrics market is projected to ... app revenue during the seven-year forecast period.    ...
(Date:7/9/2015)... July 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the fourth ... 2015 after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
... is good news for coffee lovers and growers worldwide: A ... discovered in Africa. Looking at coffee berries in Western Kenya, ... and Ecology in Kenya, Dr. Eric Chapman from the University ... thrips* Karnyothrips flavipes which feeds on ...
... a gene activity signature that predicts a high risk ... been treated with commonly used chemotherapy drugs. Despite ... breast cancers bearing this gene signature will probably still ... scientists in a letter to be published in ...
... N.Y. (January 21, 2010) Two recent, separate publications identified ... or clusters in California. Using data collected ... 2.5 million births including almost 10,000 autism cases from ... of elevated risk for autism. Autism Speaks, the ...
Cached Biology News:Natural pest control saves coffee berry 2Genes found linked to breast cancer drug resistance could guide future treatment choices 2Genes found linked to breast cancer drug resistance could guide future treatment choices 3Genes found linked to breast cancer drug resistance could guide future treatment choices 4Autism Speaks responds to recent publications citing autism clusters in California 2
...
Water Distilled (Gibco™) is membrane filtered and endotoxin screened....
Immunogen: Human Respiratory Syncytial Virus (RSV) and Bovine Respiratory Syncytial Virus (BRSV) Fusion protein Storage: -20 C, Avoid Freeze/Thaw Cycles...
Mus musculus MARCKS-like protein, mRNA...
Biology Products: